Expert Interview
Examining the recent Top-line Data from Phase 1/2 Proof-of-Concept Study of Vaxcyte's 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64
Ticker(s): PCVX, PFEDr. Kimberly Ku - MD
- Treats about 30 patients per month with Pneumococcal Disease
- Internal Medicine, Hematology Oncology with Illionois CancerCare
Dr. Ku is a general hematologist oncologist in the community setting currently seeing patients in central Illinois. In addition to treatment of disorders of all tumor types and blood disorders, Dr. Ku is also often consulted by multidisciplinary caretakers for questions related to preventative health such as vaccination schedules, cancer screenings, and genetic testing.
How would a new vaccine for pneumococcal disease change your preference for treatment?
Added By: max_adminOn a scale of 1-10 how excited are you regarding Vaxcyte's 24-Valent Pneumococcal Conjugate Vaccine Candidate?
Added By: max_adminWhat is the current standard care for someone with Pneumococcal disease
Added By: max_adminDo you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
